JP6707084B2 - アルドステロンシンターゼ阻害薬 - Google Patents

アルドステロンシンターゼ阻害薬 Download PDF

Info

Publication number
JP6707084B2
JP6707084B2 JP2017526671A JP2017526671A JP6707084B2 JP 6707084 B2 JP6707084 B2 JP 6707084B2 JP 2017526671 A JP2017526671 A JP 2017526671A JP 2017526671 A JP2017526671 A JP 2017526671A JP 6707084 B2 JP6707084 B2 JP 6707084B2
Authority
JP
Japan
Prior art keywords
dihydro
mmol
benzo
added
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017526671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536362A5 (enExample
JP2017536362A (ja
Inventor
チードン チェン
チードン チェン
デレク コーガン
デレク コーガン
シン グオ
シン グオ
ダニエル リチャード マーシャル
ダニエル リチャード マーシャル
ケネス マイケル マイアーズ
ケネス マイケル マイアーズ
ユンロン チャン
ユンロン チャン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2017536362A publication Critical patent/JP2017536362A/ja
Publication of JP2017536362A5 publication Critical patent/JP2017536362A5/ja
Application granted granted Critical
Publication of JP6707084B2 publication Critical patent/JP6707084B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017526671A 2014-12-02 2015-12-01 アルドステロンシンターゼ阻害薬 Active JP6707084B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086218P 2014-12-02 2014-12-02
US62/086,218 2014-12-02
PCT/US2015/063064 WO2016089800A1 (en) 2014-12-02 2015-12-01 Aldosterone synthase inhibitors

Publications (3)

Publication Number Publication Date
JP2017536362A JP2017536362A (ja) 2017-12-07
JP2017536362A5 JP2017536362A5 (enExample) 2019-01-17
JP6707084B2 true JP6707084B2 (ja) 2020-06-10

Family

ID=54937372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526671A Active JP6707084B2 (ja) 2014-12-02 2015-12-01 アルドステロンシンターゼ阻害薬

Country Status (4)

Country Link
US (1) US9890171B2 (enExample)
EP (1) EP3227300B1 (enExample)
JP (1) JP6707084B2 (enExample)
WO (1) WO2016089800A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110270295B (zh) * 2019-07-31 2021-08-24 北京六合宁远科技有限公司 一种氨基取代苯并吡啶含氮杂环的制备方法
JP2025540715A (ja) * 2022-11-23 2025-12-16 上▲海▼翰森生物医▲薬▼科技有限公司 ピリジン多環系化合物阻害剤、及びその製造方法と使用
KR20260009903A (ko) * 2023-05-12 2026-01-20 장쑤 더위안 파머슈티컬 코.,엘티디. 질소 함유 헤테로사이클릭 화합물 및 그의 용도
CN121586708A (zh) * 2023-07-21 2026-02-27 上海翰森生物医药科技有限公司 三并环类化合物、及其制备方法和应用
WO2025098465A1 (zh) * 2023-11-10 2025-05-15 上海齐鲁制药研究中心有限公司 稠环衍生物、其制备方法及其在医药上的应用
CN120289471B (zh) * 2024-03-01 2025-10-17 浙江扬厉医药技术有限公司 吡喃并吡啶类化合物、其制备方法、药物组合物及应用
WO2026093586A1 (en) 2024-11-04 2026-05-07 AstraZeneca Ireland Limited Combination of a aldosterone synthase inhibitor (asi) and a sodium-glucose co-transporter 2 inhibitor (sglt2i) for use in methods of reducing the risk of cardiovascular and heart failure events in a subject

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006261162A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Naphthyridine compounds
EP2993169B1 (en) * 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
MX350717B (es) * 2011-11-30 2017-09-14 Hoffmann La Roche Nuevos derivados biciclicos de dihidroisoquinolin-1-ona.
HUE035274T2 (en) * 2012-04-17 2018-05-02 Hoffmann La Roche New phenyl tetrahydroisoquinoline derivatives
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
CN105593212B (zh) * 2013-10-17 2019-06-04 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
ES2684050T3 (es) * 2014-07-24 2018-10-01 Boehringer Ingelheim International Gmbh Inhibidores de aldosterona sintasa
KR102441634B1 (ko) * 2014-10-15 2022-09-13 베링거 인겔하임 인터내셔날 게엠베하 알도스테론 신타아제 억제제

Also Published As

Publication number Publication date
WO2016089800A1 (en) 2016-06-09
US20170267688A1 (en) 2017-09-21
EP3227300B1 (en) 2019-06-19
US9890171B2 (en) 2018-02-13
JP2017536362A (ja) 2017-12-07
EP3227300A1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
JP2017536362A (ja) アルドステロンシンターゼ阻害薬
JP2023530319A (ja) Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド
US12612360B2 (en) Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
CA2964754C (en) Aldosterone synthase inhibitors
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
JP6914974B2 (ja) 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
AU2017208119B2 (en) 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
TW202530189A (zh) ３－苯基丙基胺衍生物
JP2025513454A (ja) 疼痛の治療のためのヘテロアリール化合物
TW202229254A (zh) 作為crhr2拮抗劑之3-羥基吲哚酮衍生物
CA3182610C (en) 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors
WO2026047577A1 (en) Hydroquinazoline derivatives and treatment of a disease or disorder using the same
JP5873612B2 (ja) 三環式誘導体ならびにそれらの医薬用途および組成物
JP2025513063A (ja) 新規置換フッ化ビニル－ｎ－プロピル－ピロリジン化合物、それを調製するためのプロセス及びその治療的使用
BR112017005859B1 (pt) Inibidores de aldosterona sintase, seus usos e sais farmaceuticamente aceitáveis e composição farmacêutica
HK1243068B (en) Aldosterone synthase inhibitors
HK1243068A1 (en) Aldosterone synthase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200519

R150 Certificate of patent or registration of utility model

Ref document number: 6707084

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250